Free circulating mRNA in plasma from breast cancer patients and clinical outcome

ArticleinCancer Letters 263(2):312-20 · June 2008with15 Reads
Impact Factor: 5.62 · DOI: 10.1016/j.canlet.2008.01.008 · Source: PubMed


    We studied by real-time PCR cyclin D1 and thymidylate synthase (TS) mRNA in plasma as possible markers of clinical outcome in breast cancer. We observed poor outcome in patients with presence of cyclin D1 mRNA in good-prognosis groups, such as negative vascular invasion. Presence of both markers was associated with non-response to treatment after relapse. In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Cyclin D1 mRNA in plasma could identify patients with poor overall survival in good-prognosis groups and patients non-responsive to tamoxifen.